Abstracts tagged "Safety issues"

Abstract Number: 2585 • 2018 ACR/ARHP Annual Meeting
Secukinumab Immunogenicity in Patients with Psoriatic Arthritis and Ankylosing Spondylitis during a 52-Week Treatment Period
Atul A. Deodhar¹, Dafna D Gladman², Iain B. McInnes³, Vibeke Strand⁴, Mengyuan Ren⁵, Sebastian Spindeldreher⁶, Luminita Pricop⁷, Brian Porter⁷, Jorge Safi⁷, Abhijit Shete⁸ and Gerard Bruin⁶, ¹Oregon Health & Science University, Portland, OR, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁵Novartis Pharmaceuticals, Shanghai, China, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody (mAb) that selectively targets IL-17A, is efficacious for the treatment of psoriasis, psoriatic arthritis (PsA) and ankylosing…
Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 538 • 2017 ACR/ARHP Annual Meeting
Severe Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Dalifer Freites Núñez¹, Leticia Leon¹, Juan A Jover Jover² and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. It is…
Abstract Number: 1031 • 2017 ACR/ARHP Annual Meeting
Developing a Multi-Phase Claims-Based Algorithm to Facilitate the Study of Drug Exposure during Pregnancy
S Phillips¹, KE Johnson¹, SW Shen², KJ Woodcroft³, SA Oliveria⁴ and TA Simon⁵, ¹QuintilesIMS, Seattle, WA, ²Bristol-Myers Squibb, Hopewell, NJ, ³Henry Ford Health System, Detroit, MI, ⁴QuintilesIMS, New York, NY, ⁵Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The use of antirheumatic medications during pregnancy may lead to birth defects or other complications. Safety studies are critical, with registries being common but…
Abstract Number: 1089 • 2017 ACR/ARHP Annual Meeting
Large Variations in Tuberculosis Testing for New Biologic Users with Rheumatoid Arthritis Among Providers in the RISE Registry
Gabriela Schmajuk¹, Michael Evans², Julia Kay³ and Jinoos Yazdany⁴, ¹San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Tuberculosis (TB) testing prior to biologic DMARD use helps prevent potentially fatal, medication-related adverse events and is a National Quality Forum-endorsed quality measure. We…
Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Cristina Lajas Petisco¹, Esperanza Pato Cour¹, Leticia Leon², Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 2274 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Events, Serious Infections, Uveitis, Crohn’s Disease, Colitis and Malignancies in Patients with Juvenile Idiopathic Arthritis on Continuous Treatment with Etanercept over Time: A Report from a Biologics Registry
Gerd Horneff¹, Frank Weller-Heinemann², Toni Hospach³, Prasad Oommen⁴, Gerd Ganser⁵, Johannes Peter Haas⁶, K Minden⁷ and Ariane Klein⁸, ¹Asklepios Clinic, Sankt Augustin, Germany, ²PRINTO, Genoa, Italy, ³Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁴University Duesseldorf, Duesseldorf, Germany, ⁵Pediatric Rheumatology, Sankt Josef Stift Sendenhorst, Sendenhorst, Germany, ⁶Centre for Pediatric Rheumatology Garmisch-Partenkirchen, Garmisch-Partenkirchen, Germany, ⁷Charité – University of Medicine Berlin, Berlin, Germany, ⁸Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: To investigate changes in the risk for adverse events of special interest in juvenile idiopathic arthritis (JIA) patients treated with Etanercept documented in the…
Abstract Number: 2277 • 2017 ACR/ARHP Annual Meeting
Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
Juan José Bethencourt Baute¹, Carlos Sánchez-Piedra², Lorena Expósito Pérez¹, M. Victoria Hernández³, Javier Manero⁴, Rosa Rosello⁵, Fernando Sánchez-Alonso⁶, Dolores Ruiz-Montesinos⁷, Eva Perez Pampín⁸, Carlos Rodriguez-Lozano⁹, Cristina Campos Fernandez¹⁰, Cristina Fernández-Carballido¹¹, Raquel Martín-Domenech¹¹, Javier Del Pino-Montes¹², Mercedes Freire¹³, Federico Díaz-González¹⁴, Juan J. Gomez-Reino¹⁵ and Sagrario Bustabad¹⁶, ¹Servicio de Reumatología, Hospital Universitario de Canarias, Tenerife, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁴Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ⁵Hospital San Jorge, Huesca, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Virgen Macarena, Seville, Spain, ⁸Rheumatology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁹Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁰Rheumatology, Hospital Universitario de Valencia., Valencia, Spain, ¹¹Hospital General Universitario de Elda, Elda, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ¹⁴Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ¹⁶Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The treatment of JIA has been revolutionized by the use of…
Abstract Number: 2886 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Long-Time Intensified Rituximab Treatment in Patients with Systemic Sclerosis
Hans-Peter Brezinschek¹, Sonja Kielhauser², Winfried Graninger³ and Florentine Moazedi-Fürst², ¹Internal Medicine/Division of Rheumatoloy and Immunology, Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ²Rheumatology and Immunology, Medical University Graz, Austria, Graz, Austria, ³Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: Rituximab (RTX), a monoclonal B cell depleting antibody, is one of the few new drugs that has been shown to have beneficial effects on…
Abstract Number: 120 • 2017 Pediatric Rheumatology Symposium
Use Of Thalidomide From A Tertiary Level Pediatric Rheumatology Centre In India
Manjari Agarwal¹, Abhay Shivpuri² and Sujata Sawhney³, ¹Institute of Child Health, Attending Consultant, New Delhi, India, ²Division of Pediatric Rheumatology,Institute of Child Health, Post Doctoral Fellow, New Delhi, India, ³Paediatric rheumatology, Senior Consultant, New Delhi, India
Background/Purpose: Thalidomide is an effective agent for several pediatric rheumatic diseases: Systemic onset Juvenile idiopathic arthritis(SOJIA), Behcet's disease and recalcitrant skin disease in cSLE to…
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Dalifer Freites Núñez¹, Cynthia Milagros León Cárdenas¹, Cristina Lajas Petisco¹, Leticia Leon², Luis Rodriguez Rodriguez², Juan A Jover Jover¹ and Lydia Abásolo Alcázar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…
Abstract Number: 244 • 2016 ACR/ARHP Annual Meeting
Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
Yiwen Wang¹, Dai Gao¹, Gui Luo², Kunpeng Li¹, Zheng Zhao¹ and Jian Zhu¹, ¹Rheumatology, Chinese PLA General Hospital, Beijing, China, ²Chinese PLA General Hospital, Beijing, China
Background/Purpose: Good response could be observed after applying glucocorticoids (GCs) in patients with IgG4-related disease (IgG4-RD), however, the risk of disease relapse was reported relatively…
Abstract Number: 441 • 2016 ACR/ARHP Annual Meeting
Improving Care and Avoiding Errors. Can Our Patients Recall Their Medications and Create an Accurate Medication List?
Carla F Gamarra-Hilburn and Salvador Vila, Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Medications errors are common and are an important cause of morbidity and mortality. We aimed to evaluate patient accuracy in recalling current medication use,…
Abstract Number: 1641 • 2016 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Zulema Rosales Rosado^1,2, Leticia León¹, Dalifer Freites Núñez², Judit Font Urgelles², Cynthia Milagros León Cárdenas², Cristina Vadillo Font², Luis Rodriguez Rodriguez¹, Juan A Jover Jover² and Lydia Abásolo Alcázar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: After more than twenty years using Disease Modifying Drugs (DMARDs) is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) but it…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].